ALT - Altimmune, Inc.
Altimmune, Inc.
910 Clopper Road
Suite 201S
Gaithersburg, MD 20878
United States
240-654-1450
http://www.altimmune.com
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 30
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Mitchel B. Sayare | Exec. Chairman | 109.9k | N/A | 1948 |
| Mr. William J. Enright | Pres, CEO & Director | 333.88k | N/A | 1963 |
| Dr. Sybil Tasker | Chief Medical Officer and SVP of Clinical R&D | 216.79k | N/A | 1963 |
| Mr. William Michael Brown | Acting CFO & Principal Accounting Officer | N/A | N/A | 1982 |
| Mr. Bertrand Georges Ph.D. | Chief Technology Officer | N/A | N/A | N/A |
Description
Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials. Its preclinical stage products include SparVax-L, a recombinant protein-based anthrax vaccine; and Oncosyn, an immunotherapeutic for treating cancer. The company also develops veterinary product candidates. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.
Corporate Governance
Altimmune, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
